Immunic's Vidofludimus Calcium Advances in MS Treatment: Q3 Highlights and Upcoming Milestones
ByAinvest
Thursday, Nov 13, 2025 12:16 pm ET1min read
IMUX--
Immunic Inc. CEO Daniel Vitt discussed Q3 highlights, including progress in its oral MS treatment, vidofludimus calcium. The company presented new data at ECTRIMS 2025, including positive results from the CALLIPER and EMPhASIS trials, and plans to initiate the ENSURE phase 3 trials in relapsing MS, with topline data expected in 2026. Recently granted US patents strengthen commercial protection for vidofludimus calcium, potentially extending exclusivity beyond 2041.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet